New combo therapy shows promise for aggressive breast cancer
NCT ID NCT04681768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at combining the drug abemaciclib with standard hormone therapy as a first treatment for women with metastatic breast cancer that has spread to organs or has a high tumor burden. The goal was to see how many patients' tumors shrank or disappeared. The study enrolled 95 women and tracked their response using standard imaging every 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Abemaciclib (Verzenios) plus endocrine therapy (aromatase inhibitor or Fulvestrant)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment option for patients with aggressive metastatic breast cancer, potentially improving tumor shrinkage and delaying progression.
- What could go wrong
- This is a single-arm observational study with only 95 participants, so results may not apply broadly. Side effects from abemaciclib, though manageable, can include fatigue, diarrhea, and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde
Munich, 81675, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- PET scan could reveal which breast cancer patients will respond to targeted therapy
- Could a targeted drug re-sensitize resistant breast cancer?